173 related articles for article (PubMed ID: 38354975)
1. Anthocyanins: Potential phytochemical candidates for the amelioration of non-alcoholic fatty liver disease.
Mandal B; Das R; Mondal S
Ann Pharm Fr; 2024 May; 82(3):373-391. PubMed ID: 38354975
[TBL] [Abstract][Full Text] [Related]
2. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease.
Valenti L; Riso P; Mazzocchi A; Porrini M; Fargion S; Agostoni C
Oxid Med Cell Longev; 2013; 2013():145421. PubMed ID: 24282628
[TBL] [Abstract][Full Text] [Related]
3. Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review.
Mehmood A; Zhao L; Wang Y; Pan F; Hao S; Zhang H; Iftikhar A; Usman M
Food Res Int; 2021 Apr; 142():110180. PubMed ID: 33773656
[TBL] [Abstract][Full Text] [Related]
4. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
5. Phytochemicals targeting NAFLD through modulating the dual function of forkhead box O1 (FOXO1) transcription factor signaling pathways.
Sabir U; Irfan HM; Alamgeer ; Umer I; Niazi ZR; Asjad HMM
Naunyn Schmiedebergs Arch Pharmacol; 2022 Jul; 395(7):741-755. PubMed ID: 35357518
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
7. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts.
Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH
Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
9. Fructose as a key player in the development of fatty liver disease.
Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.
Pafili K; Roden M
Mol Metab; 2021 Aug; 50():101122. PubMed ID: 33220492
[TBL] [Abstract][Full Text] [Related]
11. Grape pomace reduces the severity of non-alcoholic hepatic steatosis and the development of steatohepatitis by improving insulin sensitivity and reducing ectopic fat deposition in mice.
Daniel T; Ben-Shachar M; Drori E; Hamad S; Permyakova A; Ben-Cnaan E; Tam J; Kerem Z; Rosenzweig T
J Nutr Biochem; 2021 Dec; 98():108867. PubMed ID: 34571189
[TBL] [Abstract][Full Text] [Related]
12. A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis.
Sakuma T; Nakamura M; Chiba T; Iwanaga T; Kan M; Kojima R; Ao J; Ma Y; Unozawa H; Fujita N; Kanayama K; Kanzaki H; Koroki K; Kobayashi K; Nakagawa R; Kanogawa N; Kiyono S; Kondo T; Saito T; Ogasawara S; Nakamoto S; Muroyama R; Kato J; Kishimoto T; Kato N
Lab Invest; 2022 Oct; 102(10):1150-1157. PubMed ID: 35643859
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
14. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis.
Finck BN
Diabetes; 2018 Dec; 67(12):2485-2493. PubMed ID: 30459251
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
16. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
Brown E; Hydes T; Hamid A; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Zhou ST; Cui W; Kong L; Yang X
Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
[TBL] [Abstract][Full Text] [Related]
18. β-Sitosterol mitigates the development of high-fructose diet-induced nonalcoholic fatty liver disease in growing male Sprague-Dawley rats.
Gumede NM; Lembede BW; Nkomozepi P; Brooksbank RL; Erlwanger KH; Chivandi E
Can J Physiol Pharmacol; 2020 Jan; 98(1):44-50. PubMed ID: 31560861
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
